{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T19:24:20Z","timestamp":1786389860576,"version":"build-2736575974"},"reference-count":147,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100004515","name":"Universiti Kebangsaan Malaysia","doi-asserted-by":"publisher","award":["GGPM-2017-082"],"award-info":[{"award-number":["GGPM-2017-082"]}],"id":[{"id":"10.13039\/501100004515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2018\/SKK08\/UKM\/03\/5"],"award-info":[{"award-number":["FRGS\/1\/2018\/SKK08\/UKM\/03\/5"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2020,11,13]]},"abstract":"<jats:sec><jats:title\/><jats:p>Parkinson\u2019s Disease (PD) is one of the most common neurodegenerative disorders that affects the motor system, and includes cardinal motor symptoms such as resting tremor, cogwheel rigidity, bradykinesia and postural instability. Its prevalence is increasing worldwide due to the increase in life span. Although, two centuries since the first description of the disease, no proper cure with regard to treatment strategies and control of symptoms could be reached. One of the major challenges faced by the researchers is to have a suitable research model. Rodents are the most common PD models used, but no single model can replicate the true nature of PD. In this review, we aim to discuss another animal model, the zebrafish (Danio rerio), which is gaining popularity. Zebrafish brain has all the major structures found in the mammalian brain, with neurotransmitter systems, and it also possesses a functional blood-brain barrier similar to humans. From the perspective of PD research, the zebrafish possesses the ventral diencephalon, which is thought to be homologous to the mammalian substantia nigra. We summarize the various zebrafish models available to study PD, namely chemical-induced and genetic models. The zebrafish can complement the use of other animal models for the mechanistic study of PD and help in the screening of new potential therapeutic compounds.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871527319666200708124117","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T07:16:00Z","timestamp":1594278960000},"page":"386-399","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Modeling Parkinson\u2019s Disease in Zebrafish"],"prefix":"10.2174","volume":"19","author":[{"given":"Nor H.M.","family":"Najib","sequence":"first","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong H.","family":"Nies","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8060-6499","authenticated-orcid":true,"given":"Syarifah A.S.","family":"Abd Halim","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7155-2636","authenticated-orcid":true,"given":"Mohamad F.","family":"Yahaya","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8302-7257","authenticated-orcid":true,"given":"Srijit","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-9849","authenticated-orcid":true,"given":"Wei L.","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, School of Science and Technology, Sunway University, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9733-8072","authenticated-orcid":true,"given":"Seong L.","family":"Teoh","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"Poewe W.","year":"2017","unstructured":"Poewe W.; Seppi K.; Tanner C.M.; Parkinson disease. Nat Rev Dis Primers 2017,3,17013","journal-title":"Nat Rev Dis Primers"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1176\/jnp.14.2.223","volume":"14","author":"Parkinson J.","year":"2002","unstructured":"Parkinson J.; An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 2002,14(2),223-236","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/ageing\/afx196","volume":"47","author":"McDonald C.","year":"2018","unstructured":"McDonald C.; Gordon G.; Hand A.; Walker R.W.; Fisher J.M.; 200 Years of Parkinson\u2019s disease: What have we learnt from James Parkinson? Age Ageing 2018,47(2),209-214","journal-title":"Age Ageing"},{"key":"ref=4","first-page":"504","volume":"40","author":"DeMaagd G.","year":"2015","unstructured":"DeMaagd G.; Philip A.; Parkinson\u2019s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P 2015,40(8),504-532","journal-title":"P"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2174\/18715273113129990086","volume":"12","author":"Marques de Sousa S.","year":"2013","unstructured":"Marques de Sousa S.; Massano J.; Motor complications in Parkinson\u2019s disease: A comprehensive review of emergent management strategies. CNS Neurol Disord Drug Targets 2013,12(7),1017-1049","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","volume":"22","author":"Pfeiffer R.F.","year":"2016","unstructured":"Pfeiffer R.F.; Non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord 2016,22(Suppl. 1),S119-S122","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/jgs.12458","volume":"61","author":"Weerkamp N.J.","year":"2013","unstructured":"Weerkamp N.J.; Tissingh G.; Poels P.J.; Nonmotor symptoms in nursing home residents with Parkinson\u2019s disease: Prevalence and effect on quality of life. J Am Geriatr Soc 2013,61(10),1714-1721","journal-title":"J Am Geriatr Soc"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/472157","volume":"2014","author":"Azmin S.","year":"2014","unstructured":"Azmin S.; Khairul A.A.M.; Tan H.J.; Nonmotor symptoms in a malaysian Parkinson\u2019s disease population. Parkinsons Dis 2014,2014","journal-title":"Parkinsons Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","year":"2017","unstructured":"GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017,16(11),877-897","journal-title":"Lancet Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","year":"2018","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators. Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018,17(11),939-953","journal-title":"Lancet Neurol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","volume":"14","author":"Dehay B.","year":"2015","unstructured":"Dehay B.; Bourdenx M.; Gorry P.; Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: Mechanistic and therapeutic considerations. Lancet Neurol 2015,14(8),855-866","journal-title":"Lancet Neurol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1001\/jamaneurol.2017.0603","volume":"74","author":"Savica R.","year":"2017","unstructured":"Savica R.; Grossardt B.R.; Bower J.H.; Survival and causes of death among people with clinically diagnosed synucleinopathies with parkinsonism: A population-based study. JAMA Neurol 2017,74(7),839-846","journal-title":"JAMA Neurol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JPD-181374","volume":"8","author":"Darweesh S.K.L.","year":"2018","unstructured":"Darweesh S.K.L.; Raphael K.G.; Brundin P.; Parkinson Matters. J Parkinsons Dis 2018,8(4),495-498","journal-title":"J Parkinsons Dis"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104530","volume":"130","author":"Cicchetti F.","year":"2019","unstructured":"Cicchetti F.; David L.S.; Siddu A.; Denis H.L.; Cysteamine as a novel disease-modifying compound for Parkinson\u2019s disease: Over a decade of research supporting a clinical trial. Neurobiol Dis 2019,130","journal-title":"Neurobiol Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.chemosphere.2019.05.064","volume":"233","author":"Li B.","year":"2019","unstructured":"Li B.; Jiang Y.; Xu Y.; Li Y.; Li B.; Identification of miRNA-7 as a regulator of brain-derived neurotrophic factor\/\u03b1-synuclein axis in atrazine-induced Parkinson\u2019s disease by peripheral blood and brain microRNA profiling. Chemosphere 2019,233,542-548","journal-title":"Chemosphere"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/103094","volume":"2010","author":"Gad E.S.A.","year":"2010","unstructured":"Gad E.S.A.; Ghanem A.A.; Abdelghaffar H.; El Dakroury S.; Salama M.M.; Parkinson\u2019s disease: Is it a toxic syndrome? Neurol Res Int 2010,2010","journal-title":"Neurol Res Int"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","volume":"42","author":"Deng H.","year":"2018","unstructured":"Deng H.; Wang P.; Jankovic J.; The genetics of Parkinson disease. Ageing Res Rev 2018,42,72-85","journal-title":"Ageing Res Rev"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/0891988710383572","volume":"23","author":"Bekris L.M.","year":"2010","unstructured":"Bekris L.M.; Mata I.F.; Zabetian C.P.; The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010,23(4),228-242","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.2174\/1871527313666140806142955","volume":"13","author":"Abdel-Salam O.M.","year":"2014","unstructured":"Abdel-Salam O.M.; The paths to neurodegeneration in genetic Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 2014,13(9),1485-1512","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.adgen.2017.08.001","volume":"98","author":"Mastrangelo L.","year":"2017","unstructured":"Mastrangelo L.; The genetics of Parkinson disease. Adv Genet 2017,98,43-62","journal-title":"Adv Genet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.nbd.2014.06.009","volume":"70","author":"Dave K.D.","year":"2014","unstructured":"Dave K.D.; De Silva S.; Sheth N.P.; Phenotypic characterization of recessive gene knockout rat models of Parkinson\u2019s disease. Neurobiol Dis 2014,70,190-203","journal-title":"Neurobiol Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.3233\/JPD-181493","volume":"8","author":"Chen H.","year":"2018","unstructured":"Chen H.; Ritz B.; The search for environmental causes of Parkinson\u2019s disease: Moving forward. J Parkinsons Dis 2018,8(s1),S9-S17","journal-title":"J Parkinsons Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1212\/WNL.0b013e318294b3c8","volume":"80","author":"Pezzoli G.","year":"2013","unstructured":"Pezzoli G.; Cereda E.; Exposure to pesticides or solvents and risk of Parkinson disease. Neurology 2013,80(22),2035-2041","journal-title":"Neurology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurol.2015.09.012","volume":"172","author":"Elbaz A.","year":"2016","unstructured":"Elbaz A.; Carcaillon L.; Kab S.; Moisan F.; Epidemiology of Parkinson\u2019s disease. Rev Neurol 2016,172(1),14-26","journal-title":"Rev Neurol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1871527317666180425122557","volume":"17","author":"Yaribeygi H.","year":"2018","unstructured":"Yaribeygi H.; Panahi Y.; Javadi B.; Sahebkar A.; The underlying role of oxidative stress in neurodegeneration: A mechanistic review. CNS Neurol Disord Drug Targets 2018,17(3),207-215","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.2174\/1871527317666180809092359","volume":"17","author":"Mule N.K.","year":"2018","unstructured":"Mule N.K.; Singh J.N.; Diabetes mellitus to neurodegenerative disorders: Is oxidative stress fueling the flame? CNS Neurol Disord Drug Targets 2018,17(9),644-653","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5772\/63767","author":"Modi P.","year":"2016","unstructured":"Modi P.; Mohamad A.; Phom L.; Understanding pathophysiology of sporadic Parkinson\u2019s disease in Drosophila model: Potential opportunities and notable limitations Challenges in Parkinson\u2019s disease 2016,217-244","journal-title":"Understanding pathophysiology of sporadic Parkinson\u2019s disease in Drosophila model: Potential opportunities and notable limitations Challenges in Parkinson\u2019s disease"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.stemcr.2016.08.012","volume":"7","author":"Chung S.Y.","year":"2016","unstructured":"Chung S.Y.; Kishinevsky S.; Mazzulli J.R.; Parkin and PINK1 patient iPSC-derived midbrain dopamine neurons exhibit mitochondrial dysfunction and a-synuclein accumulation. Stem Cell Reports 2016,7(4),664-677","journal-title":"Stem Cell Reports"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/mds.25032","volume":"28","author":"Hirsch E.C.","year":"2013","unstructured":"Hirsch E.C.; Jenner P.; Przedborski S.; Pathogenesis of Parkinson\u2019s disease. Mov Disord 2013,28(1),24-30","journal-title":"Mov Disord"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2174\/1871527317666180816100203","volume":"17","author":"Kumar A.","year":"2018","unstructured":"Kumar A.; Dhawan A.; Kadam A.; Shinde A.; Autophagy and mitochondria: Targets in neurodegenerative disorders. CNS Neurol Disord Drug Targets 2018,17(9),696-705","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2174\/1389202914666131210195808","volume":"14","author":"Chai C.","year":"2013","unstructured":"Chai C.; Lim K.L.; Genetic insights into sporadic Parkinson\u2019s disease pathogenesis. Curr Genomics 2013,14(8),486-501","journal-title":"Curr Genomics"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1089\/ars.2009.2490","volume":"11","author":"Tan J.M.","year":"2009","unstructured":"Tan J.M.; Wong E.S.; Lim K.L.; Protein misfolding and aggregation in Parkinson\u2019s disease. Antioxid Redox Signal 2009,11(9),2119-2134","journal-title":"Antioxid Redox Signal"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3233\/JPD-179005","volume":"7","author":"Goedert M.","year":"2017","unstructured":"Goedert M.; Jakes R.; Spillantini M.G.; The synucleinopathies: Twenty years on. J Parkinsons Dis 2017,7(s1),S51-S69","journal-title":"J Parkinsons Dis"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neurobiolaging.2015.09.014","volume":"37","author":"Davis A.A.","year":"2016","unstructured":"Davis A.A.; Andruska K.M.; Benitez B.A.; Racette B.A.; Perlmutter J.S.; Cruchaga C.; Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiol Aging 2016,37,209","journal-title":"Neurobiol Aging"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ana.25274","volume":"84","author":"Pihlstr\u00f8m L.","year":"2018","unstructured":"Pihlstr\u00f8m L.; Blauwendraat C.; Cappelletti C.; International Parkinson disease genomics consortium; North American brain expression consortium. A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease. Ann Neurol 2018,84(1),117-129","journal-title":"Ann Neurol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/acn3.371","volume":"4","author":"Cooper C.A.","year":"2016","unstructured":"Cooper C.A.; Jain N.; Gallagher M.D.; Common variant rs356182 near SNCA defines a Parkinson\u2019s disease endophenotype. Ann Clin Transl Neurol 2016,4(1),15-25","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1089\/ars.2015.6343","volume":"24","author":"Deas E.","year":"2016","unstructured":"Deas E.; Cremades N.; Angelova P.R.; Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson\u2019s disease. Antioxid Redox Signal 2016,24(7),376-391","journal-title":"Antioxid Redox Signal"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12149-016-1099-2","volume":"30","author":"Terada T.","year":"2016","unstructured":"Terada T.; Yokokura M.; Yoshikawa E.; Extrastriatal spreading of microglial activation in Parkinson\u2019s disease: A positron emission tomography study. Ann Nucl Med 2016,30(8),579-587","journal-title":"Ann Nucl Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ana.20338","volume":"57","author":"Ouchi Y.","year":"2005","unstructured":"Ouchi Y.; Yoshikawa E.; Sekine Y.; Microglial activation and dopamine terminal loss in early Parkinson\u2019s disease. Ann Neurol 2005,57(2),168-175","journal-title":"Ann Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/1871527314666150225124928","volume":"14","author":"Macchi B.","year":"2015","unstructured":"Macchi B.; Di Paola R.; Marino-Merlo F.; Felice M.R.; Cuzzocrea S.; Mastino A.; Inflammatory and cell death pathways in brain and peripheral blood in Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 2015,14(3),313-324","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11064-011-0619-7","volume":"37","author":"Venkateshappa C.","year":"2012","unstructured":"Venkateshappa C.; Harish G.; Mythri R.B.; Mahadevan A.; Bharath M.M.; Shankar S.K.; Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: Implications for Parkinson\u2019s disease. Neurochem Res 2012,37(2),358-369","journal-title":"Neurochem Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.nucmedbio.2011.02.016","volume":"38","author":"Ikawa M.","year":"2011","unstructured":"Ikawa M.; Okazawa H.; Kudo T.; Kuriyama M.; Fujibayashi Y.; Yoneda M.; Evaluation of striatal oxidative stress in patients with Parkinson\u2019s disease using [62Cu]ATSM PET. Nucl Med Biol 2011,38(7),945-951","journal-title":"Nucl Med Biol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/j.1742-4658.2012.08491.x","volume":"279","author":"Blandini F.","year":"2012","unstructured":"Blandini F.; Armentero M.T.; Animal models of Parkinson\u2019s disease. FEBS J 2012,279(7),1156-1166","journal-title":"FEBS J"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.2174\/1871527313666140806144425","volume":"13","author":"Patil D.A.","year":"2014","unstructured":"Patil D.A.; Patil V.A.; Bari S.B.; Surana S.J.; Patil P.O.; Animal models for Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 2014,13(9),1580-1594","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2174\/1871527317666180820164250","volume":"17","author":"Fatima A.","year":"2018","unstructured":"Fatima A.; Jyoti S.; Siddique Y.H.; Models of Parkinson\u2019s disease with special emphasis on Drosophila melanogaster. CNS Neurol Disord Drug Targets 2018,17(10),757-766","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1871527317666171221110139","volume":"17","author":"Bombardi D.A.C.","year":"2018","unstructured":"Bombardi D.A.C.; Santana M.G.; di Camilo O.G.; de Oliveira C.T.P.; Priolli D.G.; Literature evidence and ARRIVE assessment on neuroprotective effects of flavonols in neurodegenerative diseases\u2019 models. CNS Neurol Disord Drug Targets 2018,17(1),34-42","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.2174\/1871527315666160920160512","volume":"15","author":"Javed H.","year":"2016","unstructured":"Javed H.; Kamal M.A.; Ojha S.; An overview on the role of a-synuclein in experimental models of Parkinson\u2019s disease from pathogenesis to therapeutics. CNS Neurol Disord Drug Targets 2016,15(10),1240-1252","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aquaculture.2007.04.077","volume":"269","author":"Lawrence C.","year":"2007","unstructured":"Lawrence C.; The husbandry of zebrafish (Danio rerio): A review. Aquaculture 2007,269,1-20","journal-title":"Aquaculture"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1016\/j.cub.2014.11.013","volume":"25","author":"Singh A.P.","year":"2015","unstructured":"Singh A.P.; N\u00fcsslein-Volhard C.; Zebrafish stripes as a model for vertebrate colour pattern formation. Curr Biol 2015,25(2),R81-R92","journal-title":"Curr Biol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.tins.2014.02.011","volume":"37","author":"Stewart A.M.","year":"2014","unstructured":"Stewart A.M.; Braubach O.; Spitsbergen J.; Gerlai R.; Kalueff A.V.; Zebrafish models for translational neuroscience research: From tank to bedside. Trends Neurosci 2014,37(5),264-278","journal-title":"Trends Neurosci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pnpbp.2014.01.022","volume":"55","author":"Kalueff A.V.","year":"2014","unstructured":"Kalueff A.V.; Echevarria D.J.; Stewart A.M.; Gaining translational momentum: More zebrafish models for neuroscience research. Prog Neuropsychopharmacol Biol Psychiatry 2014,55,1-6","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature12111","volume":"496","author":"Howe K.","year":"2013","unstructured":"Howe K.; Clark M.D.; Torroja C.F.; The zebrafish reference genome sequence and its relationship to the human genome. Nature 2013,496(7446),498-503","journal-title":"Nature"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0531-5565(02)00088-8","volume":"37","author":"Gerhard G.S.","year":"2002","unstructured":"Gerhard G.S.; Kauffman E.J.; Wang X.; Life spans and senescent phenotypes in two strains of Zebrafish (Danio rerio). Exp Gerontol 2002,37(8-9),1055-1068","journal-title":"Exp Gerontol"},{"key":"ref=54","author":"Westerfield M.","unstructured":"Westerfield M.; The zebrafish book: A guide for the laboratory use of zebrafish (Danio rerio). 4th Edition ed. Eugene: University of Oregon Press 2000"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2010.05.010","volume":"40","author":"Panula P.","year":"2010","unstructured":"Panula P.; Chen Y.C.; Priyadarshini M.; The comparative neuroanatomy and neurochemistry of zebrafish CNS systems of relevance to human neuropsychiatric diseases. Neurobiol Dis 2010,40(1),46-57","journal-title":"Neurobiol Dis"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1089\/zeb.2016.1392","volume":"14","author":"Kim S.S.","year":"2017","unstructured":"Kim S.S.; Im S.H.; Yang J.Y.; Zebrafish as a screening model for testing the permeability of blood-brain barrier to small molecules. Zebrafish 2017,14(4),322-330","journal-title":"Zebrafish"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fnana.2016.00115","volume":"10","author":"Du Y.","year":"2016","unstructured":"Du Y.; Guo Q.; Shan M.; Spatial and temporal distribution of dopaminergic neurons during development in zebrafish. Front Neuroanat 2016,10,115","journal-title":"Front Neuroanat"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"350","DOI":"10.2174\/187152712800792901","volume":"11","author":"Zhu Y.","year":"2012","unstructured":"Zhu Y.; Zhang J.; Zeng Y.; Overview of tyrosine hydroxylase in Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 2012,11(4),350-358","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00418-009-0619-8","volume":"132","author":"Chen Y.C.","year":"2009","unstructured":"Chen Y.C.; Priyadarshini M.; Panula P.; Complementary developmental expression of the two tyrosine hydroxylase transcripts in zebrafish. Histochem Cell Biol 2009,132(4),375-381","journal-title":"Histochem Cell Biol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.mcn.2010.01.006","volume":"43","author":"Yamamoto K.","year":"2010","unstructured":"Yamamoto K.; Ruuskanen J.O.; Wullimann M.F.; Vernier P.; Two tyrosine hydroxylase genes in vertebrates new dopaminergic territories revealed in the zebrafish brain. Mol Cell Neurosci 2010,43(4),394-402","journal-title":"Mol Cell Neurosci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1021\/acschemneuro.6b00014","volume":"7","author":"Ek F.","year":"2016","unstructured":"Ek F.; Malo M.; \u00c5berg A.M.; Behavioral analysis of dopaminergic activation in zebrafish and rats reveals similar phenotypes. ACS Chem Neurosci 2016,7(5),633-646","journal-title":"ACS Chem Neurosci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neuroscience.2017.08.023","volume":"362","author":"Olmedo-D\u00edaz S.","year":"2017","unstructured":"Olmedo-D\u00edaz S.; Est\u00e9vez-Silva H.; Or\u00e4dd G.; Bjerk\u00e9n A.F.S.; Marcellino D.; Virel A.; An altered blood-brain barrier contributes to brain iron accumulation and neuroinflammation in the 6-OHDA rat model of Parkinson\u2019s disease. Neuroscience 2017,362,141-151","journal-title":"Neuroscience"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s11064-016-2125-4","volume":"42","author":"Ren M.","year":"2017","unstructured":"Ren M.; Han M.; Wei X.; FTY720 attenuates 6-OHDA-associated dopaminergic degeneration in cellular and mouse Parkinsonian models. Neurochem Res 2017,42(2),686-696","journal-title":"Neurochem Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12640-017-9778-x","volume":"32","author":"Vijayanathan Y.","year":"2017","unstructured":"Vijayanathan Y.; Lim F.T.; Lim S.M.; 6-OHDA-lesioned adult zebrafish as a useful Parkinson\u2019s disease model for dopaminergic neuroregeneration. Neurotox Res 2017,32(3),496-508","journal-title":"Neurotox Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1471-4159.2004.02190.x","volume":"88","author":"Anichtchik O.V.","year":"2004","unstructured":"Anichtchik O.V.; Kaslin J.; Peitsaro N.; Scheinin M.; Panula P.; Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 2004,88(2),443-453","journal-title":"J Neurochem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1089\/zeb.2013.0950","volume":"11","author":"Feng C.W.","year":"2014","unstructured":"Feng C.W.; Wen Z.H.; Huang S.Y.; Effects of 6-hydroxy-dopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae. Zebrafish 2014,11(3),227-239","journal-title":"Zebrafish"},{"key":"ref=67","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.4957","volume":"6","author":"Benvenutti R.","year":"2018","unstructured":"Benvenutti R.; Marcon M.; Reis C.G.; N-acetylcysteine protects against motor, optomotor and morphological deficits induced by 6-OHDA in zebrafish larvae. PeerJ 2018,6","journal-title":"PeerJ"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fct.2018.06.018","volume":"119","author":"Li M.","year":"2018","unstructured":"Li M.; Zhou F.; Xu T.; Song H.; Lu B.; Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signaling pathway. Food Chem Toxicol 2018,119,6-13","journal-title":"Food Chem Toxicol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1749-8546-6-16","volume":"6","author":"Wang M.","year":"2011","unstructured":"Wang M.; Zhang Z.; Cheang L.C.; Lin Z.; Lee S.M.; Eriocaulon buergerianum extract protects PC12 cells and neurons in zebrafish against 6-hydroxydopamine-induced damage. Chin Med 2011,6,16","journal-title":"Chin Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jep.2015.04.040","volume":"170","author":"Zhang L.Q.","year":"2015","unstructured":"Zhang L.Q.; Sa F.; Chong C.M.; Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS\/NO and AKT\/GSK3\u03b2 pathways. J Ethnopharmacol 2015,170,8-15","journal-title":"J Ethnopharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuroscience.2017.10.018","volume":"367","author":"Cronin A.","year":"2017","unstructured":"Cronin A.; Grealy M.; Neuroprotective and neuro-restorative effects of minocycline and rasagiline in a zebrafish 6-hydroxydopamine model of Parkinson\u2019s disease. Neuroscience 2017,367,34-46","journal-title":"Neuroscience"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.3233\/JPD-179006","volume":"7","author":"Langston J.W.","year":"2017","unstructured":"Langston J.W.; The MPTP story. J Parkinsons Dis 2017,7,S11-S9","journal-title":"J Parkinsons Dis"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.35.7.949","volume":"35","author":"Ballard P.A.","year":"1985","unstructured":"Ballard P.A.; Tetrud J.W.; Langston J.W.; Permanent human parkinsonism due to 1\u2010methy 1-4\u2010phenyl\u20101, 2, 3, 6\u2010tetrahydropyridine (MPTP): Seven cases. Neurology 1985,35,949","journal-title":"Neurology"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"Langston JW","year":"1983","unstructured":"Langston JW; Ballard P; Tetrud JW; Irwin I; Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis 1983,219,979-80","journal-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/0024-3205(86)90037-8","volume":"39","author":"Ramsay R.R.","year":"1986","unstructured":"Ramsay R.R.; Dadgar J.; Trevor A.; Singer T.P.; Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci 1986,39,581-588","journal-title":"Life Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/B978-0-12-809468-6.00042-5","author":"Colpo G.D.","year":"2017","unstructured":"Colpo G.D.; Ribeiro F.M.; Rocha N.P.; Teixeira A.L.; Study of Human Disease Animal Models for the Study of Human Neurodegenerative DiseasesAnimal Models for the Study of Human Disease 2017,1109-1129","journal-title":"Study of Human Disease Animal Models for the Study of Human Neurodegenerative DiseasesAnimal Models for the Study of Human Disease"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1073\/pnas.82.7.2173","volume":"82","author":"Javitch J.A.","year":"1985","unstructured":"Javitch J.A.; D\u2019Amato R.J.; Strittmatter S.M.; Snyder S.H.; Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1, 2, 3, 6-tetrahydro-pyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985,82,2173-2177","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0892-0362(02)00222-2","volume":"24","author":"Speciale S.G.","year":"2002","unstructured":"Speciale S.G.; MPTP: Insights into parkinsonian neurodegeneration. Neurotoxicol Teratol 2002,24,607-620","journal-title":"Neurotoxicol Teratol"},{"key":"ref=79","first-page":"35","volume":"13","author":"Przedborski S.","year":"1998","unstructured":"Przedborski S.; Jackson-Lewis V.; Mechanisms of MPTP toxicity. Mov Disord 1998,13,35-38","journal-title":"Mov Disord"},{"key":"ref=80","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104575","volume":"132","author":"Dutta D.","year":"2019","unstructured":"Dutta D.; Kundu M.; Mondal S.; RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson\u2019s disease. Neurobiol Dis 2019,132","journal-title":"Neurobiol Dis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.neuropharm.2017.01.009","volume":"116","author":"Zheng M.","year":"2017","unstructured":"Zheng M.; Liu C.; Fan Y.; Yan P.; Shi D.; Zhang Y.; Neuroprotection by Paeoniflorin in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology 2017,116,412-420","journal-title":"Neuropharmacology"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11481-017-9732-y","volume":"12","author":"Chen X.","year":"2017","unstructured":"Chen X.; Liu Z.; Cao B.B.; Qiu Y.H.; Peng Y.P.; TGF-b1 neuroprotection via inhibition of microglial activation in a rat model of Parkinson\u2019s disease. J Neuroimmune Pharmacol 2017,12(3),433-446","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/pmic.201500291","volume":"16","author":"Sarath B.N.","year":"2016","unstructured":"Sarath B.N.; Murthy C.H.L.; Kakara S.; Sharma R.; Brahmendra S.C.V.; Idris M.M.; 1-Methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine induced Parkinson\u2019s disease in zebrafish. Proteomics 2016,16(9),1407-1420","journal-title":"Proteomics"},{"key":"ref=84","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/972391","volume":"2013","author":"Nellore J.","year":"2013","unstructured":"Nellore J.; Pauline C.; Amarnath K.; Bacopa monnieri phytochemicals mediated synthesis of platinum nanoparticles and its neurorescue effect on 1-methyl 4-phenyl 1,2,3,6 tetrahydropyridine-induced experimental Parkinsonism in zebrafish. J Neurodegener Dis 2013,2013","journal-title":"J Neurodegener Dis"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1471-4159.2008.05793.x","volume":"108","author":"Sallinen V.","year":"2009","unstructured":"Sallinen V.; Torkko V.; Sundvik M.; MPTP and MPP+ target specific aminergic cell populations in larval zebrafish. J Neurochem 2009,108(3),719-731","journal-title":"J Neurochem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s13258-015-0364-4","volume":"37","author":"Liu J.C.","year":"2015","unstructured":"Liu J.C.; Koppula S.; Huh S.J.; Necrosis inhibitor-5 (NecroX-5), attenuates MPTP-induced motor deficits in a zebrafish model of Parkinson\u2019s disease. Genes Genomics 2015,37,1073-1079","journal-title":"Genes Genomics"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.freeradbiomed.2015.08.013","volume":"89","author":"Chong C.M.","year":"2015","unstructured":"Chong C.M.; Ma D.; Zhao C.; Discovery of a novel neuroprotectant, BHDPC, that protects against MPP+\/MPTP-induced neuronal death in multiple experimental models. Free Radic Biol Med 2015,89,1057-1066","journal-title":"Free Radic Biol Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/jcb.25749","volume":"118","author":"Yao L.","year":"2017","unstructured":"Yao L.; Peng S.X.; Xu Y.D.; Unexpected neuroprotective effects of loganin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity and cell death in zebrafish. J Cell Biochem 2017,118(3),615-628","journal-title":"J Cell Biochem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.phrs.2015.11.024","volume":"103","author":"Pinho B.R.","year":"2016","unstructured":"Pinho B.R.; Reis S.D.; Guedes-Dias P.; Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson\u2019s disease. Pharmacol Res 2016,103,328-339","journal-title":"Pharmacol Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s12035-015-9198-y","volume":"53","author":"Huang C.L.","year":"2016","unstructured":"Huang C.L.; Chao C.C.; Lee Y.C.; Paraquat induces cell death through impairing mitochondrial membrane permeability. Mol Neurobiol 2016,53(4),2169-2188","journal-title":"Mol Neurobiol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1111\/ejn.14683","volume":"52","author":"Crist\u00f3v\u00e3o A.C.","year":"2020","unstructured":"Crist\u00f3v\u00e3o A.C.; Campos F.L.; Je G.; Characterization of a Parkinson\u2019s disease rat model using an upgraded paraquat exposure paradigm. Eur J Neurosci 2020,52(4),3242-3255","journal-title":"Eur J Neurosci"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1523\/JNEUROSCI.23-08-03095.2003","volume":"23","author":"Manning-Bog A.B.","year":"2003","unstructured":"Manning-Bog A.B.; McCormack A.L.; Purisai M.G.; Bolin L.M.; Di Monte D.A.; Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003,23(8),3095-3099","journal-title":"J Neurosci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.freeradbiomed.2010.02.024","volume":"48","author":"Niso-Santano M.","year":"2010","unstructured":"Niso-Santano M.; Gonz\u00e1lez-Polo R.A.; Bravo-San P.J.M.; Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2\/Trx axis. Free Radic Biol Med 2010,48(10),1370-1381","journal-title":"Free Radic Biol Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1089\/zeb.2013.0923","volume":"11","author":"Bortolotto J.W.","year":"2014","unstructured":"Bortolotto J.W.; Cognato G.P.; Christoff R.R.; Long-term exposure to paraquat alters behavioral parameters and dopamine levels in adult zebrafish (Danio rerio). Zebrafish 2014,11(2),142-153","journal-title":"Zebrafish"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.toxrep.2015.06.007","volume":"2","author":"Nellore J.P.N.","year":"2015","unstructured":"Nellore J.P.N.; Paraquat exposure induces behavioral deficits in larval zebrafish during the window of dopamine neurogenesis. Toxicol Rep 2015,2,950-956","journal-title":"Toxicol Rep"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1007\/s12035-017-0441-6","volume":"55","author":"M\u00fcller T.E.","year":"2018","unstructured":"M\u00fcller T.E.; Nunes M.E.; Menezes C.C.; Sodium selenite prevents paraquat-induced neurotoxicity in zebrafish. Mol Neurobiol 2018,55(3),1928-1941","journal-title":"Mol Neurobiol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.chemosphere.2017.10.032","volume":"191","author":"Wang X.H.","year":"2018","unstructured":"Wang X.H.; Souders C.L.; Zhao Y.H.; Martyniuk C.J.; Paraquat affects mitochondrial bioenergetics, dopamine system expression, and locomotor activity in zebrafish (Danio rerio). Chemosphere 2018,191,106-117","journal-title":"Chemosphere"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.ntt.2004.06.014","volume":"26","author":"Bretaud S.","year":"2004","unstructured":"Bretaud S.; Lee S.; Guo S.; Sensitivity of zebrafish to environmental toxins implicated in Parkinson\u2019s disease. Neurotoxicol Teratol 2004,26(6),857-864","journal-title":"Neurotoxicol Teratol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1007\/s12035-016-9919-x","volume":"54","author":"Nunes M.E.","year":"2017","unstructured":"Nunes M.E.; Muller T.E.; Braga M.M.; Chronic treatment with paraquat induces brain injury, changes in antioxidant defenses system, and modulates behavioral functions in zebrafish. Mol Neurobiol 2017,54(6),3925-3934","journal-title":"Mol Neurobiol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1007\/s11064-018-2638-0","volume":"43","author":"Horst C.H.","year":"2018","unstructured":"Horst C.H.; Schlemmer F.; de Aguiar M.N.; Signature of aberrantly expressed microRNAs in the striatum of rotenone-induced Parkinsonian rats. Neurochem Res 2018,43(11),2132-2140","journal-title":"Neurochem Res"},{"key":"ref=101","first-page":"614","volume":"8","author":"Khotimah H.","year":"2015","unstructured":"Khotimah H.; Sumitro S.B.; Aris W.M.; Zebrafish Parkinson\u2019s model: Rotenone decrease motility, dopamine, and increase \u03b1-synuclein aggregation and apoptosis of zebrafish brain. Int J Pharm Tech Res 2015,8,614-621","journal-title":"Int J Pharm Tech Res"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0748233710362382","volume":"26","year":"2010","unstructured":"Abdul wahid AI, Ahmad KH. Environmental toxins and Parkinson\u2019s disease: Putative roles of impaired electron transport chain and oxidative stress. Toxicol Ind Health 2010,26(2),121-128","journal-title":"Toxicol Ind Health"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2174\/1871527318666190905152138","volume":"18","author":"Jiang X.","year":"2019","unstructured":"Jiang X.; Tang P.C.; Chen Q.; Cordycepin exerts neuroprotective effects via an anti-apoptotic mechanism based on the mitochondrial pathway in a rotenone-induced parkinsonism rat model. CNS Neurol Disord Drug Targets 2019,18(8),609-620","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/1871527317666180816095707","volume":"18","author":"Askar M.H.","year":"2019","unstructured":"Askar M.H.; Hussein A.M.; Al-Basiony S.F.; Effects of exercise and ferulic acid on alpha synuclein and neuroprotective heat shock protein 70 in an experimental model of Parkinsonism disease. CNS Neurol Disord Drug Targets 2019,18(2),156-169","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=105","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101164","volume":"24","author":"Tapias V.","year":"2019","unstructured":"Tapias V.; McCoy J.L.; Greenamyre J.T.; Phenothiazine normalizes the NADH\/NAD+ ratio, maintains mitochondrial integrity and protects the nigrostriatal dopamine system in a chronic rotenone model of Parkinson\u2019s disease. Redox Biol 2019,24","journal-title":"Redox Biol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuro.2016.11.006","volume":"58","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Liu W.; Yang J.; Parkinson\u2019s disease-like motor and non-motor symptoms in rotenone-treated zebrafish. Neurotoxicology 2017,58,103-109","journal-title":"Neurotoxicology"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"16","DOI":"10.18192\/uojm.v5i2.1413","volume":"5","author":"Martel S.","year":"2015","unstructured":"Martel S.; Keow J.Y.; Ekker M.; Rotenone neurotoxicity causes dopamine neuron loss in zebrafish. Univ Ottawa J Med 2015,5,16-21","journal-title":"Univ Ottawa J Med"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"13926","DOI":"10.1007\/s11356-015-4596-2","volume":"22","author":"Melo K.M.","year":"2015","unstructured":"Melo K.M.; Oliveira R.; Grisolia C.K.; Short-term exposure to low doses of rotenone induces developmental, biochemical, behavioral, and histological changes in fish. Environ Sci Pollut Res Int 2015,22(18),13926-13938","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"827","DOI":"10.13005\/bpj\/1438","volume":"11","author":"Khotimah H.","year":"2018","unstructured":"Khotimah H.; Darwitri D.; Yuliyani T.; Centella asiatica increased the body length through the modulation of antioxidant in rotenone-induced zebrafish larvae. Biomed Pharmacol J 2018,11,827-833","journal-title":"Biomed Pharmacol J"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/79951","volume":"26","author":"Nasevicius A.","year":"2000","unstructured":"Nasevicius A.; Ekker S.C.; Effective targeted gene \u2018knockdown\u2019 in zebrafish. Nat Genet 2000,26(2),216-220","journal-title":"Nat Genet"},{"key":"ref=111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068708","volume":"8","author":"Hwang W.Y.","year":"2013","unstructured":"Hwang W.Y.; Fu Y.; Reyon D.; Heritable and precise zebrafish genome editing using a CRISPR-Cas system. PLoS One 2013,8(7)","journal-title":"PLoS One"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1523\/JNEUROSCI.1384-17.2017","volume":"38","author":"Pinto M.","year":"2018","unstructured":"Pinto M.; Nissanka N.; Moraes C.T.; Lack of Parkin anticipates the phenotype and affects mitochondrial morphology and mtDNA levels in a mouse model of Parkinson\u2019s disease. J Neurosci 2018,38(4),1042-1053","journal-title":"J Neurosci"},{"key":"ref=113","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104717","volume":"136","author":"Noda S.","year":"2020","unstructured":"Noda S.; Sato S.; Fukuda T.; Loss of Parkin contributes to mitochondrial turnover and dopaminergic neuronal loss in aged mice. Neurobiol Dis 2020,136","journal-title":"Neurobiol Dis"},{"key":"ref=114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011783","volume":"5","author":"Fett M.E.","year":"2010","unstructured":"Fett M.E.; Pilsl A.; Paquet D.; Parkin is protective against proteotoxic stress in a transgenic zebrafish model. PLoS One 2010,5(7)","journal-title":"PLoS One"},{"key":"ref=115","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113081","volume":"323","author":"Maynard M.E.","year":"2020","unstructured":"Maynard M.E.; Redell J.B.; Kobori N.; Loss of PTEN-induced kinase 1 (Pink1) reduces hippocampal tyrosine hydroxylase and impairs learning and memory. Exp Neurol 2020,323","journal-title":"Exp Neurol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2017.12.002","volume":"1680","author":"Kelm-Nelson C.A.","year":"2018","unstructured":"Kelm-Nelson C.A.; Brauer A.F.L.; Barth K.J.; Characterization of early-onset motor deficits in the Pink1-\/- mouse model of Parkinson disease. Brain Res 2018,1680,1-12","journal-title":"Brain Res"},{"key":"ref=117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081851","volume":"8","author":"Priyadarshini M.","year":"2013","unstructured":"Priyadarshini M.; Orosco L.A.; Panula P.J.; Oxidative stress and regulation of Pink1 in zebrafish (Danio rerio). PLoS One 2013,8(11)","journal-title":"PLoS One"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.nbd.2010.06.001","volume":"40","author":"Sallinen V.","year":"2010","unstructured":"Sallinen V.; Kolehmainen J.; Priyadarshini M.; Toleikyte G.; Chen Y.C.; Panula P.; Dopaminergic cell damage and vulnerability to MPTP in Pink1 knockdown zebrafish. Neurobiol Dis 2010,40(1),93-101","journal-title":"Neurobiol Dis"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1460-9568.2010.07091.x","volume":"31","author":"Xi Y.","year":"2010","unstructured":"Xi Y.; Ryan J.; Noble S.; Yu M.; Yilbas A.E.; Ekker M.; Impaired dopaminergic neuron development and locomotor function in zebrafish with loss of pink1 function. Eur J Neurosci 2010,31(4),623-633","journal-title":"Eur J Neurosci"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ana.23999","volume":"74","author":"Flinn L.J.","year":"2013","unstructured":"Flinn L.J.; Keatinge M.; Bretaud S.; TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency. Ann Neurol 2013,74(6),837-847","journal-title":"Ann Neurol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/ejn.13473","volume":"45","author":"Soman S.","year":"2017","unstructured":"Soman S.; Keatinge M.; Moein M.; Inhibition of the mitochondrial calcium uniporter rescues dopaminergic neurons in pink1-\/- zebrafish. Eur J Neurosci 2017,45(4),528-535","journal-title":"Eur J Neurosci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10863-019-09798-4","volume":"51","author":"Dolgacheva L.P.","year":"2019","unstructured":"Dolgacheva L.P.; Berezhnov A.V.; Fedotova E.I.; Zinchenko V.P.; Abramov A.Y.; Role of DJ-1 in the mechanism of pathogenesis of Parkinson\u2019s disease. J Bioenerg Biomembr 2019,51(3),175-188","journal-title":"J Bioenerg Biomembr"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1601-183X.2009.00559.x","volume":"9","author":"Pham T.T.","year":"2010","unstructured":"Pham T.T.; Giesert F.; R\u00f6thig A.; DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments. Genes Brain Behav 2010,9(3),305-317","journal-title":"Genes Brain Behav"},{"key":"ref=124","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104673","volume":"134","author":"Giangrasso D.M.","year":"2020","unstructured":"Giangrasso D.M.; Furlong T.M.; Keefe K.A.; Characterization of striatum-mediated behavior and neurochemistry in the DJ-1 knock-out rat model of Parkinson\u2019s disease. Neurobiol Dis 2020,134","journal-title":"Neurobiol Dis"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.brainres.2006.07.057","volume":"1113","author":"Bai Q.","year":"2006","unstructured":"Bai Q.; Mullett S.J.; Garver J.A.; Hinkle D.A.; Burton E.A.; Zebrafish DJ-1 is evolutionarily conserved and expressed in dopaminergic neurons. Brain Res 2006,1113(1),33-44","journal-title":"Brain Res"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/j.1471-4159.2006.04291.x","volume":"100","author":"Bretaud S.","year":"2007","unstructured":"Bretaud S.; Allen C.; Ingham P.W.; Bandmann O.; p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson\u2019s disease. J Neurochem 2007,100(6),1626-1635","journal-title":"J Neurochem"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"8306","DOI":"10.1007\/s12035-019-01667-w","volume":"56","author":"Edson A.J.","year":"2019","unstructured":"Edson A.J.; Hushagen H.A.; Fr\u00f8yset A.K.; Dysregulation in the brain protein profile of zebrafish lacking the Parkinson\u2019s disease-related protein dj-1. Mol Neurobiol 2019,56(12),8306-8322","journal-title":"Mol Neurobiol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1042\/BST20120151","volume":"40","author":"Sloan M.","year":"2012","unstructured":"Sloan M.; Alegre-Abarrategui J.; Wade-Martins R.; Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models. Biochem Soc Trans 2012,40(5),1080-1085","journal-title":"Biochem Soc Trans"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1750-1326-7-25","volume":"7","author":"Hinkle K.M.","year":"2012","unstructured":"Hinkle K.M.; Yue M.; Behrouz B.; LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 2012,7,25","journal-title":"Mol Neurodegener"},{"key":"ref=130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000914","volume":"6","author":"Sheng D.","year":"2010","unstructured":"Sheng D.; Qu D.; Kwok K.H.; Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet 2010,6(4)","journal-title":"PLoS Genet"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/jnr.23754","volume":"94","author":"Prabhudesai S.","year":"2016","unstructured":"Prabhudesai S.; Bensabeur F.Z.; Abdullah R.; LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation. J Neurosci Res 2016,94(8),717-735","journal-title":"J Neurosci Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","volume":"318","author":"Schober A.","year":"2004","unstructured":"Schober A.; Classic toxin-induced animal models of Parkinson\u2019s disease: 6-OHDA and MPTP. Cell Tissue Res 2004,318(1),215-224","journal-title":"Cell Tissue Res"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2174\/1871527316666170623094728","volume":"16","author":"Radad K.","year":"2017","unstructured":"Radad K.; Moldzio R.; Al-Shraim M.; Kranner B.; Krewenka C.; Rausch W.D.; Recent advances on the role of neurogenesis in the adult brain: Therapeutic potential in Parkinson\u2019s and Alzheimer\u2019s diseases. CNS Neurol Disord Drug Targets 2017,16(7),740-748","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"29490","DOI":"10.1038\/srep29490","volume":"6","author":"Antinucci P.","year":"2016","unstructured":"Antinucci P.; Hindges R.; A crystal-clear zebrafish for in vivo imaging. Sci Rep 2016,6,29490","journal-title":"Sci Rep"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrd4627","volume":"14","author":"MacRae C.A.","year":"2015","unstructured":"MacRae C.A.; Peterson R.T.; Zebrafish as tools for drug discovery. Nat Rev Drug Discov 2015,14(10),721-731","journal-title":"Nat Rev Drug Discov"},{"key":"ref=136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035645","volume":"7","author":"Sun Y.","year":"2012","unstructured":"Sun Y.; Dong Z.; Khodabakhsh H.; Chatterjee S.; Guo S.; Zebrafish chemical screening reveals the impairment of dopaminergic neuronal survival by cardiac glycosides. PLoS One 2012,7(4)","journal-title":"PLoS One"},{"key":"ref=137","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.172828","volume":"189","author":"Vaz R.L.","year":"2020","unstructured":"Vaz R.L.; Sousa S.; Chapela D.; Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model. Pharmacol Biochem Behav 2020,189","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10571-011-9731-0","volume":"32","author":"Zhang Z.J.","year":"2012","unstructured":"Zhang Z.J.; Cheang L.C.; Wang M.W.; Ethanolic extract of fructus Alpinia oxyphylla protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. Cell Mol Neurobiol 2012,32(1),27-40","journal-title":"Cell Mol Neurobiol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neulet.2013.02.069","volume":"543","author":"Chong C.M.","year":"2013","unstructured":"Chong C.M.; Zhou Z.Y.; Razmovski-Naumovski V.; Danshensu protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. Neurosci Lett 2013,543,121-125","journal-title":"Neurosci Lett"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbadis.2010.09.011","volume":"1812","author":"Kabashi E.","year":"2011","unstructured":"Kabashi E.; Brustein E.; Champagne N.; Drapeau P.; Zebrafish models for the functional genomics of neurogenetic disorders. Biochim Biophys Acta 2011,1812(3),335-345","journal-title":"Biochim Biophys Acta"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jgg.2012.07.008","volume":"39","author":"Wang K.","year":"2012","unstructured":"Wang K.; Huang Z.; Zhao L.; Large-scale forward genetic screening analysis of development of hematopoiesis in zebrafish. J Genet Genomics 2012,39(9),473-480","journal-title":"J Genet Genomics"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jgg.2012.07.004","volume":"39","author":"Huang P.","year":"2012","unstructured":"Huang P.; Zhu Z.; Lin S.; Zhang B.; Reverse genetic approaches in zebrafish. J Genet Genomics 2012,39(9),421-433","journal-title":"J Genet Genomics"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nmeth.3360","volume":"12","author":"Shah A.N.","year":"2015","unstructured":"Shah A.N.; Davey C.F.; Whitebirch A.C.; Miller A.C.; Moens C.B.; Rapid reverse genetic screening using CRISPR in zebrafish. Nat Methods 2015,12(6),535-540","journal-title":"Nat Methods"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2174\/1389450117666160527142321","volume":"18","author":"Chakraborty C.","year":"2017","unstructured":"Chakraborty C.; Teoh S.L.; Das S.; The smart programmable CRISPR technology: A next generation genome editing tool for investigators. Curr Drug Targets 2017,18(14),1653-1663","journal-title":"Curr Drug Targets"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1086\/374383","volume":"72","author":"Pankratz N.","year":"2003","unstructured":"Pankratz N.; Nichols W.C.; Uniacke S.K.; Parkinson Study Group- Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet 2003,72(4),1053-1057","journal-title":"Am J Hum Genet"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ajhg.2008.01.015","volume":"82","author":"Lautier C.","year":"2008","unstructured":"Lautier C.; Goldwurm S.; D\u00fcrr A.; Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet 2008,82(4),822-833","journal-title":"Am J Hum Genet"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.neurobiolaging.2009.12.016","volume":"32","author":"Guella I.","year":"2011","unstructured":"Guella I.; Pistocchi A.; Asselta R.; Mutational screening and zebrafish functional analysis of GIGYF2 as a Parkinson-disease gene. Neurobiol Aging 2011,32(11),1994-2005","journal-title":"Neurobiol Aging"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183554\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/183554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T16:02:05Z","timestamp":1723219325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183554\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":147,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527319666200708124117","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}